Cost-Effectiveness Analysis of a Randomized Trial Comparing Care Models for Chronic Kidney Disease
- 1 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 6 (6), 1248-1257
- https://doi.org/10.2215/cjn.07180810
Abstract
Background and objectives Potential cost and effectiveness of a nephrologist/nurse–based multifaceted intervention for stage 3 to 4 chronic kidney disease are not known. This study examines the cost-effectiveness of a chronic disease management model for chronic kidney disease. Design, setting, participants, & measurements Cost and cost-effectiveness were prospectively gathered alongside a multicenter trial. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (CanPREVENT) randomized 236 patients to receive usual care (controls) and another 238 patients to multifaceted nurse/nephrologist–supported care that targeted factors associated with development of kidney and cardiovascular disease (intervention). Cost and outcomes over 2 years were examined to determine the incremental cost-effectiveness of the intervention. Base-case analysis included disease-related costs, and sensitivity analysis included all costs. Results Consideration of all costs produced statistically significant differences. A lower number of days in hospital explained most of the cost difference. For both base-case and sensitivity analyses with all costs included, the intervention group required fewer resources and had higher quality of life. The direction of the results was unchanged to inclusion of various types of costs, consideration of payer or societal perspective, changes to the discount rate, and levels of GFR. Conclusions The nephrologist/nurse–based multifaceted intervention represents good value for money because it reduces costs without reducing quality of life for patients with chronic kidney disease.Keywords
This publication has 22 references indexed in Scilit:
- A Nurse-coordinated Model of Care versus Usual Care for Stage 3/4 Chronic Kidney Disease in the CommunityClinical Journal of the American Society of Nephrology, 2011
- Opportunities for Improving Management of Advanced Chronic Kidney DiseaseAmerican Journal of Medical Quality, 2008
- Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsBMJ, 2008
- Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature reviewClinical and Experimental Nephrology, 2008
- Prevalence of Chronic Kidney Disease and Survival among Aboriginal PeopleJournal of the American Society of Nephrology, 2007
- Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney diseaseNephrology Dialysis Transplantation, 2006
- Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)Clinical Therapeutics, 2006
- Identifying Individuals with a Reduced GFR Using Ambulatory Laboratory Database SurveillanceJournal of the American Society of Nephrology, 2005
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized TrialAnnals of Internal Medicine, 2001